View all cases
UPC CFI 29/2026
Jan 5, 2026·EP3689383 Unitary patent · CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
- Case details
- StatusWritten PhaseActionInfringementCategoryMain infringement action
- Parties
- Claimants
- 2seventy bio, Inc.Operating co.
Representatives- Thomas Wolter-Mewburn Ellis LLP
- Eliot Ward-Mewburn Ellis LLP
- Matthew Naylor-Mewburn Ellis LLP
- Amy Crouch-Mewburn Ellis LLP
- Camilla Balleny-Mewburn Ellis LLP
- Sean Jauss-Mewburn Ellis LLP
- Alex Galbraith-Mewburn Ellis LLP
- Anja Koller
- Lauren Woolley-Mewburn Ellis LLP
- Liam Batty-Mewburn Ellis LLP
Respondents- Johnson & JohnsonOperating co.
- Janssen Biotech, Inc.Operating co.
- Janssen Pharmaceuticals Inc.Operating co.
- Janssen-Cilag International NVOperating co.
- Janssen Pharmaceutica NVOperating co.
- Janssen-Cilag NVOperating co.
- Janssen Biologics B.V.Operating co.
- Janssen-Cilag B.V.Operating co.
- Janssen-Cilag GmbHOperating co.
- Janssen-CilagOperating co.
- Janssen-Cilag SpAOperating co.
- Janssen-Cilag A/SOperating co.
- Janssen-Cilag AktiebolagOperating co.
- Janssen-Cilag Farmaceutica Lda.Operating co.
- Legend Biotech CorporationOperating co.
- Legend Biotech USA Inc.Operating co.
- Legend Biotech Ireland LimitedOperating co.
- Legend Biotech Belgium BVOperating co.
Representatives- Pauline Debré-Linklaters LLP
- Daan Frederik de Lange-Brinkhof
- Andreas Obermeier-Bird & Bird LLP
- Annika Lückemann-Bird & Bird LLP
- Domien Op de Beeck-Bird & Bird LLP
- Division
- Brussels LD
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- English
- First decided
- Sep 23, 2026
- EPO Opposition
- Boult Wade Tennant LLPAdmissible2025-12-31
- Legend Biotech Ireland LimitedAdmissible2026-09-29
- STRAWMAN LIMITEDAdmissible2026-09-29
- Lang, SvenAdmissible2026-09-30
- Keltie LLPAdmissible2026-09-30
- Hampton Knowles LimitedAdmissible2026-09-30
- Janssen Pharmaceutica NVAdmissible2026-09-30
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
| Infringement found | Median days to first decision | |
|---|---|---|
| All UPC | 53% (62/117) | 124 |
| Brussels LD | Locked | Locked |
| Judge Samuel Granata | Locked | Locked |
| Judge Marije Knijff | Locked | Locked |
| Judge Anna-Lena Klein | Locked | Locked |
| Judge Renaud Fulconis | — | Locked |
At the UPC: 2seventy bio, Inc. (2 cases)·Janssen Group (11 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 1 other proceedings
Start a free trial to see how each one ended.
More cases: Brussels LD·2026
Decisions
- 2026-09-23InfringementPublic
Summary: The Brussels Local Division refused the NIH's request to be treated as co-claimant in 2seventy bio's infringement action over EP 3 689 383 (while holding it defendant in the counterclaims for revocation), and dismissed the Janssen and Legend defendants' R. 190 applications for production of evidence on entitlement and on prior notice under Art. 47 UPCA; costs were referred to the final proceedings.
Show the legal issues (4)
- Intervener cannot be reclassified as co-claimant (R. 305, R. 315 RoP); no 'aggressive' interventions
- Presumption of entitlement under R. 8.4 RoP rebuttable on substantive law; entitlement may be raised as a defence
- Production of evidence (R. 190 RoP) requires plausibility of the underlying claims
- Prior notice under Art. 47(2)/(3) UPCA assessed when the action is recorded in the register; burden on the claimant
Documents
Show all 562 documents| Document title | Date | Public |
|---|---|---|
| Receipt | 2026-10-05 | Not public |
| Cover sheet | 2026-10-05 | Not public |
| Statement of rejoinder | 2026-10-05 | Not public |
| Exhibit Defendant | 2026-10-05 | Not public |
| Exhibit Defendant | 2026-10-05 | Not public |
| Exhibit Defendant | 2026-10-05 | Not public |
| Exhibit Defendant | 2026-10-05 | Not public |
| Exhibit Defendant | 2026-10-05 | Not public |
| Exhibit Defendant | 2026-10-05 | Not public |
| Exhibit Defendant | 2026-10-05 | Not public |